This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of the current review is to determine if combined modality therapy (chemoradiation) improves all-cause mortality and/or local control in patients with anal carcinoma. To this end, we aim to obtain individual patient data (IPD) for analysis.
The comparison of different chemoradiation regimens as primary treatments of anal cancer is the subject of a further review.
To quantify the magnitude of benefit (if one exists) through multiple other dimensions including colostomy rates and resectability of recurrent tumour.
To perform a subgroup analysis to test the a priori hypothesis that there is no difference in local control rates for radiotherapy versus chemoradiation for small anal cancers.
To determine the harms (early and late) of chemoradiation versus radiotherapy alone in patients with anal carcinoma.
To assess the positive or negative effects on quality of life of chemoradiation versus radiotherapy alone for anal carcinoma.
To assess the cost effectiveness of chemoradiation versus radiotherapy alone for anal carcinoma.